ArticleMetabolic brain disease2025
Tanshinone IIA inhibits neuronal ferroptosis and relieves cerebral ischemia‒reperfusion injury by regulating miR-449a/ACSL4.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Research Progress on Programmed Cell Death in Ischemic Stroke and Intervention with Chinese Medicine.Chinese journal of integrative medicine · 2026Review
- Research progress on the molecular mechanisms of tanshinone IIA in the treatment of cardiovascular and cerebrovascular diseases (Review).International journal of molecular medicine · 2026Review
- Protective Effect of Chinese Herbal Medicine on Cerebral Ischemia-Reperfusion Injury by Regulating Ferroptosis.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral ischemia‒reperfusion injury (CI/RI) plays a significant role in the initiation of ischemic stroke. This study aimed to explore the influence of Tan (tanshinone) IIA in the treatment of neuronal ferroptosis induced by CI/RI, along with the associated molecular mechanisms. A CI/RI model was created by occluding the middle cerebral artery in rats (MCAO/R). A cellular CI/RI model was established with SH-SY5Y cells that were subjected to oxygen‒glucose deprivation followed by subsequent reperfusion (OGD/R). The optimal concentration for maintaining cell viability was evaluated through the CCK-8 assay. The expression levels of ferroptosis and oxidative stress-related genes in rat brain tissue and SH-SY5Y cells were determined, and the molecular mechanism by which Tan IIA regulates ferroptosis during CI/RI treatment was verified by bioinformatics analysis, RT‒qPCR, and dual-luciferase reporter assays. The results revealed that Tan IIA relieved CI/RI injury and inflammation by inhibiting ferroptosis in MCAO/R rat brain neurons. Our experimental results demonstrated that Tan IIA suppressed the progression of OGD/R and alleviated inflammation in SH-SY5Y cells. Ferroptosis affected the concentrations of Fe
Indexed as
Identifiers
40542896What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.